Curaway Medical completes several hundred million RMB Series C financing to build intelligent tumor intervention platform, leading the era of smart-controlled precision tumor ablation

Recently, CuraWay Medical, a leading Chinese company in the interventional field, announced the completion of a several hundred million RMB Series C financing round. This round was co-invested by a number of well-known industrial funds, with continued participation from existing shareholders. The proceeds will be primarily used for the clinical application and commercial promotion of new intelligent interventional technologies, accelerating the construction of a minimally invasive interventional platform covering the entire process of "diagnosis, treatment, and intelligent localization."

In response to the clinical trend of increasingly precise and minimally invasive tumor treatment, CuraWay Medical has successfully established a domestically leading, three-pronged intelligent tumor intervention product matrix consisting of "percutaneous interventional navigation robot, precision energy ablation, and smart biopsy and consumables." This matrix covers the complete clinical pathway from diagnosis, precise localization, and intelligent navigation to ablative therapy, enabling full-process empowerment across key tumor intervention procedures.

Leveraging this full-stack layout, CuraWay Medical has become one of the few companies in China capable of providing a complete solution for tumor intervention, deeply aligning with the evolving needs of medical institutions for integrated procurement, synergistic efficacy, and standardized quality control. Additionally, the company is developing safe and effective cutting-edge technologies for complex hepatobiliary and pancreatic vital organs that are otherwise untreatable, as well as for a broader range of smart application scenarios. The company has received multiple authoritative recognitions, including being named a National "Little Giant" Specialized and Sophisticated Enterprise by the Ministry of Industry and Information Technology, and a Provincial Enterprise Research Institute by the  Economy and Information Technology Department of Zhejiang Province, demonstrating official endorsement of its technological strength and industry position.

Recently, the National Healthcare Security Administration and multiple provincial and municipal bureaus have successively issued and published formal reimbursement catalogs for innovative medical services such as surgical robots, explicitly including robot-assisted surgery in the medical service pricing items and granting a significant technological premium. This landmark policy has completely removed the "last mile" barrier from technological implementation to clinical adoption of surgical robots.

Against this significant favorable policy backdrop, CuraWay Medical's percutaneous interventional surgical robot, with its clear clinical value (improved puncture accuracy, reduced complications, and lower radiation exposure), forms a synergistic advantage with the company's supporting interventional devices. This financing round will significantly accelerate the company's commercialization process, allowing it to seize the first-mover advantage in the market.

In 2025, CuraWay Medical was recognized as one of the Top 50 Most Valuable Innovative Enterprises in Zhejiang by the Zhejiang Venture Capital Association, and has been listed among the Hangzhou Unicorn and Quasi-Unicorn Enterprises for multiple consecutive years. The successful completion of this several hundred million RMB financing round represents the full recognition by both new and existing shareholders of CuraWay Medical's "technological depth, product breadth, and strategic vision." This financing marks a key milestone in the company's development. CuraWay Medical will continue to pursue its strategy of "innovation-driven, clinical-focused, and globally positioned," continuously expanding research and development into more intelligent application scenarios, accelerating the internationalization of its comprehensive solutions, and bringing Chinese minimally invasive treatment solutions to patients around the world.